

1. Coleman NC. Beneficial liaisons: radiobiology meets cellular and molecular biology. *Radiother Oncol* 1993, 28, 1-15.
2. Crompton NEA, Hain J, Jaussi R, Burkart W. Staurosporine and radiation induced G2 phase cell cycle blocks are equally released by caffeine. *Radiother Res* 1993, 135, 372-379.
3. Hallahan D, Haimovitz-Friedman A, Kufe DW, Fuks Z, Weichselbaum RR. The role of cytokines in radiation oncology. In DeVita V, Hellman S, Rosenberg SA, eds. *Important Advances in Oncology* 1993. Philadelphia, JB Lippincott, 1993, ch. 5, 71-80.
4. Harris CC, Hollstein M. Clinical implications of the p53 tumor-suppressor gene. *N Engl J Med* 1992, 329, 18, 1318-1327.
5. Kerr JFR, Winterford CM, Harmon BV. Apoptosis. Its significance in cancer and cancer therapy. *Cancer* 1994, 73, 2013-2026.
6. Maity A, McKenna G, Muschel R. The molecular basis for cell cycle delays following ionizing radiation: a review. *Radiother Oncol* 1994, 31, 1-13.
7. Oren M. Relationship of p53 to the control of apoptotic cell death. *Semin Cancer Biol* 1994, 5, 221-227.
8. Ward JF. The yield of DNA double strand breaks produced intracellularly by ionising radiation: a review. *Int J Radiat Biol* 1990, 57, 1141-1150.
9. Weichselbaum R, Fuks Z, Hallahan D, Haimovitz-Friedman A, Kufe D. Radiation-induced cytokines and growth factors: cellular and molecular basis of the modification of radiation damage. In Yarnold, Stratton, McMillan, eds. *Molecular Biology for Oncologists*. Amsterdam, Elsevier, 1993.

## News

### New Appointment

Dr Alberto Costa, Executive Director of the European School of Oncology, has been elected to the position of Secretary of the Federation of European Cancer Societies. Dr Costa will take up office immediately after ECCO 8 in November this year. He will serve for a period of 2 years and replaces Professor Emmanuel van der Schueren.

### EORTC New Drug Development Office—Vacancy

The EORTC New Drug Development Office (NDDO) is the executive office of the EORTC research division and as such is responsible for the coordination of a comprehensive anticancer drug development programme in Europe. The office covers all the essential preclinical and clinical development stages such as screening, formulation, toxicology as well as Phase I and early Phase II clinical trials. Studies are performed in collaboration with EORTC-cooperative groups and the international pharmaceutical industry. The EORTC-NDDO is located at the Free University Hospital in Amsterdam, The Netherlands. The EORTC-NDDO at present has 17 employees; the director is supported by a multi-disciplinary staff consisting of a medical oncologist, pharmacist and biologist and including advisors in automation, finances and biostatistics.

The EORTC invites applicants for the position of director. The applicant should be an M.D. with extensive experience in medical oncology, preferably holding a PhD degree. Expertise in the clinical pharmacology of cytotoxic agents, as well as in the coordination of cancer research programmes is required. Previous administrative experience, and leadership/multilingual skills are necessary. Applicants should send a letter of intent, CV and names of three referees within 2 weeks to the President of the Foundation NDDO: MR R.J. Vless, c/o Advocatenkantoor Ekelmans-Den Hollander, P.O. Box 545, 1000 AM Amsterdam, The Netherlands; Tel: 31-20-553-3600. For more information, please contact the above address. Applicants are informed that there is an internal candidate.

### The Division of Colon and Rectal Surgery of the University of Minnesota Medical School

The 2nd Annual Conference, "Molecular Biology of Colorectal Cancer", will be held at the University of Minnesota, Minneapolis campus, on 12 September 1995. The fee is \$125 and

the accreditation is 7 hours, Category 1-AMA. For further information, please contact Continuing Medical Education, University of Minnesota, Radisson Hotel Metrodome, Suite 107, 615 Washington Avenue S.E., Minneapolis, Minnesota 55414, U.S.A.; or call (612) 626-7600; toll free 1-800-776-8636; Fax: (612) 626-7766.

### Second University of Chicago Symposium. Concomitant Chemoradiotherapy for Solid Tumours. Symposium Director: Everett E. Vokes M.D.

This will be held between 28 and 29 September 1995 at the Ritz Carlton Hotel, Chicago, Illinois, U.S.A. For further information, please contact The Center for Continuing Medical Education, The University of Chicago, 6019 South Kimbark, Box 129, Chicago, Illinois 60637, U.S.A.; Tel: (312) 702-1056; Fax: (312) 702-1736.

### Chemotherapy Foundation Symposium XIII, Innovative Cancer Chemotherapy for Tomorrow

This conference will be held between 1 and 3 November 1995 at the Crowne Plaza in New York and is sponsored by the Division of Neoplastic Diseases and the Post-Graduate School of the Mount Sinai School of Medicine with Ezra M. Greenspan M.D. as Chairman. For a programme and further information, please contact Jaclyn Silverman, Division of Neoplastic Diseases, Box 1178, Mount Sinai School of Medicine, One Gustave Levy Place, New York, New York 10029, U.S.A.; Tel: (212) 241-6772; Fax: (212) 996-5787.

### The International Society For Haematology and Graft Engineering (ISHAGE)

The 2nd International Meeting of this Society is being held between 21 and 23 June 1995 in Vancouver, Canada. In three action packed days, you will attend Plenary and Scientific Update Forums featuring leaders in the field, including keynote speaker, Dr E. Donnell Thomas. In addition, standards, accreditation and regulatory issues that affect your laboratory and clinical practice will be discussed, and technical workshops at both a basic and advanced level will be held. For further information, please contact Stephanie Hudson, Conference Organizer, Terry Fox Laboratory, 601 West 10th Avenue, Vancouver, B.C., Canada, V5Z 1L3; Tel: (604) 875-4961; Fax: (604) 875-5053.